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ABSTRACT
The purpose of this study was to compare contemporary risk of hip fracture in type 1 and type 2 diabetes with the nondiabetic
population. Using a national diabetes database, we identiﬁed those with type 1 and type 2 diabetes who were aged 20 to 84 years and
alive anytime from January 1, 2005 to December 31, 2007. All hospitalized events for hip fracture in 2005 to 2007 for diabetes patients
were linked and compared with general population counts. Age‐ and calendar‐year‐adjusted incidence rate ratios were calculated by
diabetes type and sex. One hundred ﬁve hip fractures occurred in 21,033 people (59,585 person‐years) with type 1 diabetes; 1421 in
180,841 people (462,120 person‐years) with type 2 diabetes; and 11,733 hip fractures over 10,980,599 person‐years in the nondiabetic
population (3.66 million people). Those with type 1 diabetes had substantially elevated risks of hip fracture compared with the general
population incidence risk ratio (IRR) of 3.28 (95% conﬁdence interval [CI] 2.52–4.26) inmen and 3.54 (CI 2.75–4.57) inwomen. The IRRwas
greater at younger ages, but absolute risk difference was greatest at older ages. In type 2 diabetes, there was no elevation in risk among
men (IRR 0.97 [CI 0.92–1.02]) and the increase in risk in women was small (IRR 1.05 [CI 1.01–1.10]). There remains a substantial elevation
relative risk of hip fracture in people with type 1 diabetes, but the relative risk is much lower than in earlier studies. In contrast, there is
currently little elevation in overall hip fracture risk with type 2 diabetes, but this may mask elevations in risk in particular subgroups of
type 2 diabetes patients with different bodymass indexes, diabetes duration, or drug exposure. © 2014 The Authors. Journal of Bone and
Mineral Research published by Wiley Periodicals, Inc. on behalf of the American Society for Bone and Mineral Research. This is an open
access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited.
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Introduction
Hip fractures are an important cause of mortality andmorbidity, especially in the elderly. They account for the
majority of fracture‐related health‐care expenditure and mortali-
ty in men and women over the age of 50 years within the
European Union.(1) Case fatality for hip fracture is high, with
relative hazard for all‐cause mortality in the ﬁrst 3 months after
fracture of 5.75 (95% conﬁdence interval [CI] 4.94–6.67) in
women and 7.95 (CI 6.13–10.30) in men.(2)
Previous studies have shown that type 1 diabetes is
associated with an increased risk of hip fracture. Vestergaard
combined studies in ameta‐analysis and concluded that the risk
ratio for hip fracture in type 1 diabetes excluding one outlier
was elevated sevenfold.(3) The observed risks vary between
individual studies, and many studies are very small. There have
been more studies in type 2 diabetes, but the results are less
consistent. Large studies have generally shown a smaller
increase in relative risk compared with the general popula-
tion(4,5) than found in type 1 diabetes, whereas smaller studies
show no signiﬁcant elevation in risk.(6–8) A systematic review
and meta‐analysis in 2007 concluded that the relative risk of hip
fracture in type 2 diabetes compared with the nondiabetic
population was 1.38.(3) However, the majority of published
studies for both type 1 and type 2 diabetes are now several years
old, and data collection in some cases goes as far back as 1975 in
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type 19 and 1970 in type 2 diabetes.(6) Over the past 20 years,
there have been many changes in the management of diabetes
that might alter the relative risks of fracture associated with
diabetes; there have been improvements in glycemic control,
earlier detection of type 2 diabetes, reductions in the prevalence
of renal failure, and changes in drug treatments that may
inﬂuence fracture risk, eg, introduction of thiazolidinediones.(10)
Many of the above studies report relative risks that are an
average of risks pertaining tomany years and so reﬂect historical
risks.(4,6,9,11,12) To establish the contemporary risks of hip
fracture associated with diabetes, we used a nationwide
diabetes register and data from the total nondiabetic popula-
tion for Scotland. We focused on hip fractures because these are
comprehensively captured by hospital admission data, our main
source of outcome data. Unlike many previous studies, we were
able to examine contemporary risks, and unlike previous studies
of type 1 diabetes, we were able to examine risks across all age
bands, not just younger persons.
Materials and Methods
Ethics statement
Approval was obtained from the Scotland A Research Ethics
Committee, Privacy (Caldicott) Guardians for the 14 Scottish
Health Boards, and the Scottish Privacy Advisory Committee.
Data sources
In Scotland, a single nationwide clinical information system, the
Scottish Care Information‐Diabetes Collaboration (SCI‐DC) data-
base, has captured registration of patients with diabetes since
2000. Registration occurs automatically when a Read code for
diabetes is assigned in primary or secondary care. Because all but
5 of 1076 general practices nationwide contribute data, it is
estimated to capture more than 99% of all those with diagnosed
diabetes. From a 2008 extract of SCI‐DC, we extracted
information on all people with type 1 and type 2 diabetes
aged 20 to 84 years who were alive at any time between
January 1, 2005, and December 31, 2007, inclusive. We included
cases prevalent at January 2005 (n¼ 19,083 type 1 and
n¼ 144,480 type 2) and cases incident by December 31, 2007
(n¼ 2625 and n¼ 50,673).
We deﬁned type 1 diabetes on the basis of the type of diabetes
assigned in the database with the additional requirement that
the prescription history did not contradict this (ie, no evidence of
lengthy period of diabetes before insulin and no coprescribing of
nonmetformin oral diabetes drugs). Type 2 diabetes was deﬁned
as either a recorded diagnosis of type 2 diabetes or a diagnosis of
type 1 diabetes that was contradicted by clinical history and
prescription data. We identiﬁed all hospitalized events for hip
fracture for type 1 and type 2 diabetes patients in 2005 to 2007
by linkage of the diabetes register to national hospital
admissions data (the Scottish Morbidity Record SMR‐01) held
by the Information Services Division (ISD) of NHS National
Services. Death data provided by the National Records of
Scotland were used for right censoring follow‐up time in those
with diabetes. The SMR‐01 data set captures all national public
sector hospital admissions from 1981 onward.(13) ISD also
provided the counts of events and midyear population
denominators for the total general population of Scotland
aged >20 years for 2005 to 2007. Hip fracture events were
deﬁned as hospital admissions with any of the ICD‐10 codes
S72.0, S72.1, or S72.2 as the main admission reason.
Statistical methods
Analysis was carried out using STATA 11.1 (StataCorp, College
Station, TX, USA). Data for the total population were available in
the form of counts of persons with an event in each calendar
year, with the correspondingmidyear population estimates as an
approximation of the person years, broken down by sex,
individual age bands, and quintiles of Scottish Index of Multiple
Deprivation (SIMD). To obtain counts of persons with events and
denominators for the nondiabetic population, we collapsed age
into 5‐year age bands and subtracted from the midyear total
population all those with any type of diabetes at any point in that
year and we subtracted from the total count of persons with
events all those with diabetes who had an event at any point in
that year.
Individual level data on those with type 1 and type 2 diabetes
were grouped similarly to give counts of persons with events in
each calendar year and the total person‐years observed within
each calendar year. Age‐adjusted incidence rate ratios (IRRs)
were calculated, analyzing men and women separately using
negative binomial or Poisson models, whichever gave the better
ﬁt as assessed by the Akaike Information Criterion.(14) As data on
the general population was provided by SIMD, this covariate was
included in all analyses. The IRRs associated with diabetes for a
given attained age/sex group therefore represent the average
effect of diabetes in that group across the 3 years of the study
compared with those without any type of diabetes. IRR
calculations were restricted to end December 2007 because
partial year data for 2008 were not available for the nondiabetic
population. Models adjust for the effect of calendar year as a
linear trend and adjust for age using 5‐year age bands (except
that we used a wider 20‐ to 29‐year age band in type 1 diabetes
because events were too sparse otherwise in this age band) and
deprivation. Where there was evidence of an interaction
between the effect of diabetes and age, we estimated the effect
of diabetes separately for 10‐year age bands while still adjusting
for the main effect of age in 5‐year age bands. Absolute risk
differences were calculated as the difference in age‐adjusted
rates within age bands between the groups under comparison.
There were relatively few individuals with type 2 diabetes
under age 40 years (4966 observed across the 3‐year study
period, of whom 505 were aged under 30 years). In this group,
there was only one event in men in the time period and none in
women. At the other end of the age spectrum, we were not able
to make an age‐adjusted comparison of diabetes with the
nondiabetic population aged 85 years and older because
the general population data do not provide ﬁner breakdown
for that age band. We, therefore, restricted all analyses to
subjects aged 20 to 84 years for type 1 diabetes, and 40 to
84 years for type 2 diabetes.
Because body mass index (BMI) is increased in type 2 diabetes
but higher BMI is a protective factor for fracture, we also
examined the relative risk of hip fracture compared with the
nondiabetic population for each tertile of BMI among the type 2
diabetic population. Note that in this analysis the comparator
rates are for the nondiabetic population becausewe did not have
BMI data on the nondiabetic population.
Results
There were 21,033 people with type 1 diabetes aged 20 to
84 years and 180,841 people with type 2 diabetes aged 40 to
84 years observable during the time period described. This
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equates to 59,585 and 462,120 person‐years, and 105 and 1421
events, respectively. This was compared with 3.66 million people
and 10,980,599 person‐years, with 11,733 events for the general
nondiabetic population. Fig. 1 summarizes rates of fracture by
age, with the expected marked increase in incidence of hip
fracture with age.
Type 1 diabetes
Table 1 shows the crude rates and IRRs for type 1 diabetes and
the nondiabetic population. Type 1 diabetes was clearly
associated with an increased risk of fracture in both men and
women. The observed IRR for type 1 diabetes in women was
similar to the IRR in men (3.54 [95% conﬁdence interval (CI) 2.75–
4.57] versus 3.28 [95% CI 2.52–4.26], respectively). Nonetheless,
all analyses are stratiﬁed by sex because this gives models with
better ﬁt and allows for the differing pattern of fracture by age
between sexes. The observed IRRs are generally highest in the
age bands where the background absolute rates are lower, ie, in
the younger populations. The absolute risk difference between
men with type 1 diabetes and nondiabetic subjects generally
increased with age from 0.42 in those aged 20 to 39 years to 2.78,
5.47, and 7.33 per 1000 person‐years in those aged 60 to 69, 70 to
79, and 80 to 84 years, respectively. In women, the absolute risk
difference increased from 0.16 in those aged 20 to 39 years to
3.93, 8.07, and 21.88 per 1000 person‐years in those aged 60 to
69, 70 to 79, and 80 to 84 years, respectively.
Type 2 diabetes
Table 2 shows hip fracture rates for type 2 diabetes, showing a
different pattern in comparison with the nondiabetic population
from that observed among people with type 1 diabetes. The
overall age‐adjusted IRRwas 0.97 (95%CI 0.92–1.02), p¼ 0.234, in
men and 1.05 (95% CI 1.01–1.10), p¼ 0.013, in women. In men,
there was little evidence for an effect of type 2 diabetes in any
age group, and the absolute risk differences between type 2
diabetes and nondiabetic populations were small, with the
greatest difference (0.84 per 1000 person‐years) in the oldest age
group. Inwomen, the IRRs for type 2 diabetes varied considerably
by age and were statistically different from unity in all but the
youngest and oldest of these age groups (Table 2). However, the
absolute risk differences were also small, the greatest difference
being 0.9 per 1000 person‐years for those aged 70 to 79 years.
When stratiﬁed by tertile of BMI among the diabetic population
however, those in the bottom tertile for BMI had higher hip
fracture risks than the overall risks in the background
nondiabetic population, and those in the upper two tertiles for
BMI have signiﬁcantly lower rates (Table 3). Risks also varied by
diabetes duration, with those type 2 diabetes patients in the top
tertile for duration (>7 years) having signiﬁcantly increased risks
in both sexes (IRR 1.25 in men [95% CI 1.08–1.45]; IRR 1.55 in
women [95% CI] 1.38–1.75).
Discussion
This study gives a contemporary picture of the risk of hip fracture
in people with diabetes. Although our results clearly show an
increased risk of hip fracture in type 1 diabetes, among those
with type 2 diabetes the overall rates of fracture are consistent
with those seen in the general population. However, this overall
picture in type 2 diabetes masks a more subtle pattern of risks in
subgroups; among those with type 2 diabetes, elevated relative
risks are seen in both sexes in those with longer diabetes
duration and in those in the bottom tertile for BMI. The strengths
of this study lie in the large sample size and comprehensive
capture of thosewith diabetes in Scotland, which enable the risks
measured to be truly representative and free of selection bias.
The large sample size and recent time span of the data have
allowed us to provide accurate up‐to‐date estimates of risk.
However, even with our large sample size, sparse numbers of
events in lower age groups mean the results need to be
interpreted with some caution for these age bands.
The body of work on type 1 diabetes and fracture risk is small,
mostly because of the comparatively low prevalence of type 1
diabetes. Many studies are limited by very small sample sizes and
low event rates, such as the Tromsø study,(8) which had only 81
people with type 1 diabetes and only 8 nonvertebral fractures in
the 6 years of follow‐up from 1994 to 2001 with resulting
estimates of risk withwide conﬁdence intervals (17.8 [5.6–56.8] in
men, 8.6 [1.2–61.5] in women) compared with those without
Fig. 1. (A) Rates of hip fracture in those with type 1 diabetes compared with the nondiabetic population, standardized by age and deprivation category
(SIMD). Black square¼men with type 1 diabetes; white square¼men without diabetes; black circle¼women with type 1 diabetes; white
square¼womenwithout diabetes. (B) Rates of hip fracture in those with type 2 diabetes compared with the nondiabetic population, standardized by age
and deprivation category (SIMD). Black square¼men with type 2 diabetes; white square¼men without diabetes; black circle¼women with type 2
diabetes; white square¼women without diabetes. Note that the age range is 20 to 84 years in type 1 but 40 to 84 years in type 2.
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diabetes. The study covered a wide range of ages from 25 years
upward. Similarly, the Nurses’ Health Study (1976 to 2002),
although large overall, had only 18 women with type 1
diabetes.(12) Here the age‐adjusted relative risk (RR) for hip
fracture was 7.1 (4.4–11.4), which is higher than our estimate. The
population was older than the one presented here, with a mean
age over 55 years. Nicodemus and Folsom found 5 fractures in 47
postmenopausal women with type 1 diabetes (a relative risk of
12), in a total population of 32,089 in the Iowa Women’s Health
Study followed from 1986 to 1997 with an entry age of 55 years
upward.(11) These earlier studies have all found higher risks than
we ﬁnd but will not reﬂect recent changes in themanagement of
type 1 diabetes and are consequently unlikely to represent a
contemporary estimate of risk.
The only study to show a lower risk than described here was
Vestergaard and colleagues, who in 2000 in Denmark performed
a large case‐control study including 10,530 hip fractures from the
national discharge registry with linkage to national prescription
data.(15) Diabetes was ascertained from the discharge registry as
well as prescription data. An odds ratio of 1.7 (1.31–2.21) for hip
fracture in type 1 diabetes versus no diabetes was reported.(15) It
is not clear why these lower relative rates were found in this
study; the authors discuss the possibility of misclassiﬁcation of
diabetes in controls. Certainly we know that type 2 diabetes
Table 1. Incidence Rates and Incidence Rate Ratio (IRR) of Hip Fracture Hospitalization Event in Those With Type 1 Diabetes Compared
With the Nondiabetic Population
Age band
(years)
Type 1 diabetes Nondiabetic
Crude rate per
1000 person‐
years (SE)
Adjusteda
incidence
rate ratio
95%
confidence
interval p Value
No. of
events
Person‐
years
Crude rate per 1000
person‐years (SE)
No. of
events
Person‐
years
Men
20–39 7 14,391 0.49 (0.18) 143 1,977,521 0.07 (0.01) 6.35 (3.44–11.72) <0.001
40–49 7 8975 0.78 (0.29) 188 1,101,017 0.17 (0.01) 4.40 (2.48–7.81) <0.001
50–59 4 5792 0.69 (0.35) 369 930,837 0.40 (0.02) 1.79 (0.60–5.34) 0.299
60–69 11 2877 3.82 (1.15) 697 670,970 1.04 (0.04) 3.79 (2.18–6.56) <0.001
70–79 11 1280 8.59 (2.59) 1314 420,833 3.12 (0.09) 2.95 (1.88–4.62) <0.001
80–84 3 200 15.02 (8.67) 872 113,365 7.69 (0.26) 1.96 (0.62–6.18) 0.251
Total (20–84) 43 33,515 1.28 (0.20) 3583 5,214,543 0.69 (0.01) 3.28 (2.52–4.26) <0.001
Women
20–39 2 11,407 0.18 (0.12) 39 2,038,897 0.02 (0.00) 8.92 (2.22–35.81) 0.002
40–49 5 6519 0.77 (0.34) 121 1,189,870 0.10 (0.01) 7.47 (3.11–17.93) <0.001
50–59 13 4104 3.17 (0.88) 459 988,934 0.46 (0.02) 7.13 (4.24–11.99) <0.001
60–69 13 2397 5.42 (1.50) 1141 767,643 1.49 (0.04) 3.81 (2.69–5.38) <0.001
70–79 19 1373 13.84 (3.17) 3341 578,686 5.77 (0.10) 2.59 (1.61–4.16) <0.001
80–84 10 270 36.97 (11.69) 3049 202,026 15.09 (0.27) 2.50 (1.28–4.88) 0.007
Total (20–84) 62 26,070 2.38 (0.30) 8150 5,766,056 1.41 (0.02) 3.54 (2.75–4.57) <0.001
aIncidence rate ratio is adjusted for age, calendar year, SIMD, and for the overall estimate, an SIMD‐age interaction.
Table 2. Incidence Rates and IRRs of Hip Fracture Hospitalization Event in Those With Type 2 Diabetes Compared With the Nondiabetic
Population
Age band
(years)
Type 1 diabetes Nondiabetic
Crude rate per
1000 person‐
years (SE)
Adjusteda
incidence
rate ratio
95%
confidence
interval p Value
No. of
events
Person‐
years
Crude rate per 1000
person‐years (SE)
No. of
events
Person‐
years
Men
40–49 4 25,033 0.16 (0.08) 188 1,101,017 0.17 (0.01) 0.87 (0.47–1.61) 0.656
50–59 34 58,347 0.58 (0.10) 369 930,837 0.40 (0.02) 1.14 (0.93–1.39) 0.214
60–69 69 80,582 0.86 (0.10) 697 670,970 1.04 (0.04) 0.87 (0.76–1.00) 0.046
70–79 228 71,606 3.18 (0.21) 1314 420,833 3.12 (0.09) 1.00 (0.94–1.06) 0.921
80–84 119 17,367 6.85 (0.63) 872 113,365 7.69 (0.26) 0.95 (0.86–1.04) 0.248
Total (40–84) 454 252,935 1.79 (0.08) 3440 3,237,022 1.06 (0.02) 0.97 (0.92–1.02) 0.234
Women
40–49 3 17,258 0.17 (0.10) 121 1,189,870 0.10 (0.01) 1.19 (0.63–2.21) 0.594
50–59 30 37,814 0.79 (0.14) 459 988,934 0.46 (0.02) 1.21 (1.04–1.41) 0.013
60–69 134 61,744 2.17 (0.19) 1141 767,643 1.49 (0.04) 1.14 (1.08–1.21) <0.001
70–79 468 70,156 6.67 (0.31) 3341 578,686 5.77 (0.10) 1.06 (1.01–1.12) 0.032
80–84 332 22,213 14.95 (0.82) 3049 202,026 15.09 (0.27) 0.99 (0.92–1.07) 0.841
Total (40–84) 967 209,185 4.62 (0.15) 8111 3,727,159 2.18 (0.02) 1.05 (1.01–1.10) 0.013
aIncidence rate ratio adjusted for age, calendar year, SIMD, and for the overall estimate, an SIMD‐age interaction.
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patients on insulin are often mislabeled as having type 1
diabetes; this could reduce the odds ratio in that study but only if
it were differential between cases and controls. The only
prospective study of a size comparable to ours is Miao and
colleagues, who enrolled 24,605 people with type 1 diabetes
from 1975 to 1988 in Sweden. The mean age at enrollment was
20.7 years (SD 10.9), and there was a mean 10‐year follow‐up.(9)
Hospitalization ratios (SHR) standardized for age, sex, and
calendar year for hip fracture in the population with type 1
diabetes was 7.6 (5.9–9.6) in men and 9.8 (7.3–12.9) for women
compared with the nondiabetic population. The risk ratios were
higher for those aged over 40 years. We found overall relative
risks lower than that reported by Miao and colleagues and that
the relative risks fell with age. Vestergaard3 combined studies,
excluding one outlier study, in a meta‐analysis and concluded
that the risk ratio for hip fracture in type 1 diabetes was 6.94 (95%
CI 3.25–14.78). We have shown in our study that type 1 diabetes
is associated with a substantially increased risk of hip fracture,
emphasizing the need for a greater understanding of the cause
of increased fracture and preventive strategies in type 1 diabetes.
However, our data also show that the relative risks are nowhere
near as large as in some earlier studies. Because we found that
relative risks are lower with older attained ages, some of the
differencesmay be owing to amore truncated age distribution in
some of these earlier studies. However, the differences are
sufﬁciently large as to suggest that improvements in type 1
diabetes management may have resulted in a narrowing of the
excess risk associated with type 1 diabetes. We cannot assess this
directly, but certainly previous studies8,11 have suggested that
the greatest risk elevation is found in those with more
nephropathic and cardiovascular complications, so measures
to reduce these might be expected to have impacted on the
fracture risk, too. However, whether improved glycemic control,
blood pressure management, or increased statin use, all of which
have occurred,(16) or some other aspect of management may be
responsible is not known.
Studies in type 2 diabetes patients speciﬁcally are more
frequent and have larger populations. Despite this, they still
often derive estimates over a long period of time so that the risk
may not necessarily reﬂect contemporary risks. The risks
reported from these studies of people with type 2 diabetes
vary substantially. Melton and colleagues, for example, followed
their population from 1970 until 1994, showing no signiﬁcant
effect of diabetes on fracture in women over that time period,
and a small increase in risk for men.(6) Giangregorio and
colleagues4 observed 3518 men and women with diabetes and
36,085 controls aged over 50 years with valid FRAX scores from
1990 to 2007, and showed an age‐related hazard ratio after
adjusting for FRAX score risk factors of 6.27 (3.62–10.87) under
65 years and 2.2 (1.71–2.90) aged 65 years and over. The
Cardiovascular Health Study recruited patients aged over
65 years from 1989 to 1993, then rerecruited in 2005 to
2006.(7) Of 5641 people, 918 had diabetes of unspeciﬁed type,
contributing 8428 person‐years of diabetes. Age, sex, and
race‐adjusted hazard ratio was 1.05 (0.80–1.39). Bazelier and
colleagues matched 180,049 people with type 2 diabetes to
490,147 nondiabetic controls, aged over 18 years, with mean of
follow‐up of 5.3 years for those with diabetes and 6.2 years
for controls from 1996 to 2007. They found the same incidence of
fractures in both groups (3.1%), but a hazard ratio of 1.21 (1.18–
1.23) for those on antidiabetic medication versus nondiabetics
after adjustment for age and sex.(5) The Tromsø study found
slightly higher but nonsigniﬁcant hazard ratios in the population
with type 2 diabetes (1.5 [0.5–4.0] inmen, 1.7 [1.0–3.0] in women)
from 1994 to 2001.(8) Nicodemus and Folsom11 showed an age‐
adjusted relative risk of hip fracture of 1.75 (1.25–2.43) in type 2
diabetes compared with the nondiabetic population. These data
were collected from 1986 to 1997 in a population aged over
60 years, so the higher age of the population and the protracted
period of data acquisition make comparison with contemporary
data difﬁcult. The Nurses’ Health Study showed elevated RRs for
type 2 diabetes as well as type 1 diabetes, (age‐adjusted RR for
hip fracture 1.7 [1.4–2.0] in type 2 diabetes) from 1998 to 2002.(12)
Again, the data are not contemporary and the population
signiﬁcantly older, so comparisons are limited. The Women’s
Health Initiative study has a larger population with type 2
diabetes but covered an earlier time period (1975 to 1998), and
was also limited to an older population (mean age at screening
was over 64 years). They showed a modest increase in age‐
adjusted relative risk for hip fracture of 1.41 (1.17–1.70).(17)
Vestergaard and colleagues in Denmark in 2000 performed a
case‐control study of fractures including 10,530 hip fractures,
and showed an odds ratio of 1.4 (1.2–1.6) for those with type 2
diabetes compared with no diabetes.(15)
Vestergaard also summarized the extensive literature up to
2007 in type 2 diabetes in a meta‐analysis and concluded that
the relative risk for hip fracture was 1.38 (1.25–1.53).(3) That
analysis drew attention to the heterogeneity in relative risks for
overall fracture risk in type 2 diabetes. The meta‐analysis also
reported decreased bonemineral density in type 1 diabetes and
increased bone mineral density in type 2 diabetes. Another
meta‐analysis found a higher summary relative risk for hip
fracture of 1.7 (1.3–2.2), possibly reﬂecting the use of
confounder‐adjusted estimates.(18) The observed differences
in relative risk between the oldest and most recent studies
discussed were small, and none of the above studies examined
in detail whether there was a time trend in the data available.
Thus the estimates from meta‐analyses of hip fracture relative
risk in type 2 diabetes, mostly encompassing study periods
much earlier than our study, show an elevated risk for hip
fracture in type 2 diabetes comparedwith our ﬁnding of a lack of
elevation in risk in men and amuch smaller elevation in women.
Table 3. Incidence Risk Ratios for Hip Fracture in Type 2 Diabetes Versus Nondiabetic Population by Tertile of BMI in ThoseWith Diabetes
Sex Tertile BMI (kg/m2) IRR (95% CI)a p Value
Men 1 15.0–27.8 1.34 (1.17–1.55) <0.001
2 27.9–32.1 0.63 (0.51–0.76) <0.001
3 32.3–79.4 0.48 (0.36–0.62) <0.001
Women 1 14.1–28.0 1.53 (1.36–1.73) <0.001
2 28.1–33.8 0.74 (0.62–0.89) 0.001
3 33.9–79.9 0.57 (0.45–0.73) <0.001
aReference category is the total nondiabetic population.
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It is possible that our results reﬂect an improvement in relative
risk associated with type 2 diabetes, but we cannot test this
directly. There are several factors that might be expected to
operate to alter the risks among people with type 2 diabetes in
either direction; for example, type 2 diabetes is getting detected
earlier so that our lower risks might reﬂect a greater prevalence
of patients with shorter durations than earlier studies; this would
lower relative risks because longer duration of diabetes has
been associated with increased risks,(3) and we also found that
here. Trends in BMI might also alter the risks through time or
between studies. It has been suggested that in type 2 diabetes
the elevated BMI may be acting to reduce risk, whereas diabetes
per se is increasing risk.(3) Our data are consistent with this idea
in that those in the top tertile of BMI had lower risks than the
background population and those with the lower tertiles had
elevated risks. Relevant to this is that the proportion of our type
2 population who are obese has risen from 44% in 2003 to 55%
in 2011.(19) Reduction in complications, especially renal disease
risk, might also impact. However, there are factors operating
that would be expected to increase risks for fracture in type 2
diabetes, too. In particular, we and others have shown that use
of thiazolidinediones is associated with increased hip fracture
risk in our type 2 diabetes population.(10)
An important consideration is whether our results are
affected by misclassiﬁcation of exposure or outcome. Details
of the sensitivity and speciﬁcity of our diabetes registry are
provided elsewhere, but in brief we estimate that more than
99% of all diagnosed patients are captured because all but ﬁve
primary‐care practices nationally contribute to the register. The
register is used to invite patients for retinopathy screening and
less that 4% of invitations are rejected as being sent to a
nondiabetic individual, ie, speciﬁcity is high. Type of diabetes is
validated against diagnosis date and drug history. Of course,
undiagnosed type 2 diabetes is not captured, but inclusion of
such persons would be expected to result in an even slightly
lower relative risk because their duration would be on average
less. With respect to hip fracture capture, the data here pertain to
hospitalization for hip fracture, so do not capture those who do
not present to hospital. However, nonhospitalized hip fracture is
rare: In our data, for example, comparing admissions against
national death records, we did not identify anyone with hip
fracture listed as cause of death without a preceding hospital
admission. With regard to coding of hip fracture hospitalizations,
a comparison against the Scottish Hip Fracture Audit showed
complete capture of hip fractures by hospital discharge codes.(20)
Thus we are conﬁdent that the data we report are a good
representation of risks in people with diagnosed diabetes.
In summary, we conclude that there remains a substantial
elevation relative risk of hip fracture in people with type 1
diabetes, but the relative risk is much lower than in earlier studies.
In contrast, overall there is currently little elevation in hip fracture
risk with type 2 diabetes, but this may mask elevations in risk, in
particular subgroups of type 2 diabetes patients with different
BMI or diabetes duration or drug exposure. Future work will
address key determinants of hip fracture in those with type 1 and
type 2 diabetes, allowing further development of individual‐level
hip fracture risk prediction for those with diabetes.
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